𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparative account of serum lipids, lipoproteins and apolipoprotein-B in patients of coronary artery disease

✍ Scribed by Ritu Sharma; Mridula Mahajan; Ravi Kant


Publisher
Association of Clinical Biochemistry of India
Year
2004
Tongue
English
Weight
287 KB
Volume
19
Category
Article
ISSN
0970-1915

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Lipoproteins and Apolipoproteins in the
✍ Assmann, G. πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons βš– 922 KB

Based on the results of the Prospective Cardiovascular Miinster Study (PROCAM-Trial), new possibilities are shown which permit the recognition of a coronary risk or the prediction of the likelihood of amyocardial infarction. Practical problems in the classification oflipid metabolismdisordersare dis

A multicenter comparison of nicorandil a
✍ Jun Sasaki; Yoshihisa Saeki; Kazuya Kawasaki; Morio Umeno; Kenjiro Ikeda; Koichi πŸ“‚ Article πŸ“… 1992 πŸ› Springer US 🌐 English βš– 328 KB

The effects of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in 37 patients with ischemic heart disease were examined in a randomized, multicenter study. Nicorandil (n = 20, 10-40 mg/day, b.i.d.) and diltiazem (n = 17, 60-240 mg/day, b.i.d.) were administered for 12

Effect of Apolipoprotein E genotypes on
✍ Soudabeh Fallah; Morteza Seifi; Mohsen Firoozrai; Ladan Hosainnee Ghohari; Ali S πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 1 views

Background: Apolipoprotein (apo) E polymorphism plays a significant role in the development of coronary disease, but their involvement in coronary artery stenosis (CAS) is controversial. Therefore, the purpose of this study was to investigate the effects of this polymorphism on atherosclerosis, and

Association of elevated lipoprotein(a) l
✍ J. Ruiz; J. Thillet; T. Huby; R. W. James; D. Erlich; P. Flandre; P. Froguel; J. πŸ“‚ Article πŸ“… 1994 πŸ› Springer 🌐 English βš– 824 KB

Non-insulin-dependent diabetes mellitus (NIDDM) is a strong and independent risk factor for cardiovascular and coronary heart disease mortality [1]. Established risk factors, including glucose intolerance, arterial hypertension, central obesity, hypercholesterolaemia or hypertriglyceridaemia, have b